Please login to the form below

Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.

Litigation concerns threaten to overshadow solid quarter at J&J

Growth for immunology therapy Stelara (ustekinumab) and blood cancer drugs Imbruvica (ibrutinib) and Darzalex (daratumumab) – plus Stelara follow-up Tremfya (guselkumab) – outweighed the effect of generic competition to older prostate cancer
J&J's Tremfya filed for approval in US for psoriatic arthritis

Tremfya (guselkumab) is Janssen’s follow-up to IL-23/IL-12 inhibitor blockbuster Stelara (ustekinumab), which has faced competition from rival new treatments across immunology indications. ... AbbVie’s Humira and J&J’s Stelara have remained
Second TULIP trial resurrects AZ’s lupus drug anifrolumab

There are some encouraging signs with other drugs however, including mid-stage clinical results with Incyte/Eli Lilly’s Olumiant (baricitinib), Johnson &Johnson’s IL-12/IL-23 inhibitor Stelara (ustekinumab)
FDA clears Lilly’s Taltz for ankylosing spondylitis

That includes TNF inhibitors and drugs in the IL-12/IL-23 inhibitor category - which includes Janssen’s Stelara (ustekinumab) - although Lilly has also suggested it may be eating into the
NICE’s fast-track catapults Skyrizi into market

NICE noted in its final appraisal in June that clinical trials shows Skyrizi is more effective than AbbVie’s Humira (adalimumab) and J&J’s IL-12/IL-23 inhibitor Stelara ... Of the newer agents, Stelara was the most prescribed, with expenditure at

More from news
Approximately 14 fully matching, plus 70 partially matching documents found.

Drug launches to watch in 2019

The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were
Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Back to the future

Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10